improvement of cognitive performance after administration of fampridina in patients with multiple sclerosis
What it found
A paper reports the results; we have not read it yet. See Papers below.
What was tested
Treatment tested
- Dalfampridine
Voltage-gated potassium channel blocker
What it measured
Main measures
To analyze the effects of the drug on speed of information processing measured with Symbol Digit Modalities Test (SDMT)
Thinking and memory
Other measures (1)
EVALUATION BY the Stroop test (ST)) ; the Tower of London (TOW), the PASAT, Selective Reminding Test (SRT), e 10/36 Spatial Recall Test .
Thinking and memory
Who could take part
MS (type not specified)
Inclusion: age from 18 to 65 years (inclusive); Exclusion: clinical relapse occurred in the previous 60 days;
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
To analyze the effects of the drug on cognitive function in MS patients measured with Symbol Digit Modalities Test (SDMT).
Papers
Results
Dalfampridine to Improve Balance in Multiple Sclerosis: Substudy from a Randomized Placebo-Controlled Trial.Neurotherapeutics · 2020
Results
Effect of dalfampridine on information processing speed impairment in multiple sclerosis.Neurology · 2019
Loading reviews and guidelines…
Related trials
- AmpPT
Phase 3 · Recruiting
Still running
- RESTORE
Phase 3 · Stopped early
Stopped: not working
- New strategies in neurological diseases
Phase 4 · Ongoing
Still running
- MUST
Not a drug-phase study · Completed
Result in a paper, not read yet
- FAMILY
Completed
Result in a paper, not read yet
- Fampridine Study in Activities of Daily Living
Phase 4 · Completed
No result found
History
Started
Oct 2013
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error